Stryker Corporation

New York Stock Exchange
Back to all articles
Bullish +75

Stryker: Q1 Earnings Snapshot

📈 Stryker reported first-quarter profit of $592 million, beating Wall Street expectations.

💰 Adjusted earnings per share reached $2.14, exceeding the average analyst estimate of $2.00.

💵 Revenue totaled $4.78 billion for the quarter, surpassing the consensus forecast of $4.55 billion.

🚀 The company raised its full-year earnings guidance to a range of $10.05 to $10.25 per share.

📊 Results were based on data from Zacks Investment Research and reported by AP News.

Bullish Signals
  • Stryker's first-quarter profit of $592 million significantly exceeded market expectations, demonstrating strong financial execution.
  • Adjusted earnings per share of $2.14 beat the average analyst estimate of $2.00, indicating robust underlying business performance.
  • Revenue of $4.78 billion surpassed the Street forecast of $4.55 billion, highlighting effective top-line growth.
  • The company raised its full-year earnings guidance to $10.05-$10.25 per share, reflecting confidence in future profitability.
Full Analysis
Stryker Corp. (SYK) reported first-quarter earnings that exceeded Wall Street expectations, driven by strong revenue and profit performance. The Kalamazoo, Michigan-based medical device manufacturer posted a quarterly profit of $592 million, translating to $1.54 per share on the reported basis. On an adjusted basis, which excludes amortization and non-recurring costs, Stryker's earnings reached $2.14 per share, surpassing the average analyst estimate of $2.00 per share provided by Zacks Investment Research. The company also generated revenue of $4.78 billion for the quarter, beating the consensus forecast of $4.55 billion set by a group of ten analysts. Looking ahead to the full year, Stryker has raised its earnings guidance, projecting annual earnings per share in the range of $10.05 to $10.25. This positive outlook follows a quarter where both top-line revenue and bottom-line profitability outperformed market predictions, signaling continued operational strength for the medical technology leader.